Literature DB >> 6321612

Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis.

I Kubonishi, I Miyoshi.   

Abstract

A new hematopoietic cell line, designated KCL-22, was established in vitro by cultivation of pleural effusion cells obtained from a woman with chronic myelogenous leukemia in blast crisis. KCL-22 grew in suspension culture with a doubling time of 24 h and consisted of immature undifferentiated cells which were positive for periodic acid-Schiff and acid phosphatase staining. Chromosome analysis of the KCL-22 line showed a female karyotype with double Ph1 chromosomes and additional chromosome abnormalities. Its representative karyotype was 52,XX, + 1p-,+6,+8,+8,+8, t(9q+;22q-), +22q-. This cell line possessed receptors for the Fc portion of IgG, but lacked lymphoid cell characteristics and the Epstein-Barr virus-associated nuclear antigen. These results indicate that the KCL-22 cells were derived from chronic myelogenous leukemia cells. This cell line should prove useful for research involving various aspects of chronic myelogenous leukemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6321612     DOI: 10.1002/stem.5530010205

Source DB:  PubMed          Journal:  Int J Cell Cloning        ISSN: 0737-1454


  28 in total

1.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

Authors:  Hyo-eun C Bhang; David A Ruddy; Viveksagar Krishnamurthy Radhakrishna; Justina X Caushi; Rui Zhao; Matthew M Hims; Angad P Singh; Iris Kao; Daniel Rakiec; Pamela Shaw; Marissa Balak; Alina Raza; Elizabeth Ackley; Nicholas Keen; Michael R Schlabach; Michael Palmer; Rebecca J Leary; Derek Y Chiang; William R Sellers; Franziska Michor; Vesselina G Cooke; Joshua M Korn; Frank Stegmeier
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

2.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Authors:  King Pan Ng; Axel M Hillmer; Charles T H Chuah; Wen Chun Juan; Tun Kiat Ko; Audrey S M Teo; Pramila N Ariyaratne; Naoto Takahashi; Kenichi Sawada; Yao Fei; Sheila Soh; Wah Heng Lee; John W J Huang; John C Allen; Xing Yi Woo; Niranjan Nagarajan; Vikrant Kumar; Anbupalam Thalamuthu; Wan Ting Poh; Ai Leen Ang; Hae Tha Mya; Gee Fung How; Li Yi Yang; Liang Piu Koh; Balram Chowbay; Chia-Tien Chang; Veera S Nadarajan; Wee Joo Chng; Hein Than; Lay Cheng Lim; Yeow Tee Goh; Shenli Zhang; Dianne Poh; Patrick Tan; Ju-Ee Seet; Mei-Kim Ang; Noan-Minh Chau; Quan-Sing Ng; Daniel S W Tan; Manabu Soda; Kazutoshi Isobe; Markus M Nöthen; Tien Y Wong; Atif Shahab; Xiaoan Ruan; Valère Cacheux-Rataboul; Wing-Kin Sung; Eng Huat Tan; Yasushi Yatabe; Hiroyuki Mano; Ross A Soo; Tan Min Chin; Wan-Teck Lim; Yijun Ruan; S Tiong Ong
Journal:  Nat Med       Date:  2012-03-18       Impact factor: 53.440

3.  Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.

Authors:  Mio Yamamoto-Sugitani; Junya Kuroda; Eishi Ashihara; Hisao Nagoshi; Tsutomu Kobayashi; Yosuke Matsumoto; Nana Sasaki; Yuji Shimura; Miki Kiyota; Ryuko Nakayama; Kenichi Akaji; Tomohiko Taki; Nobuhiko Uoshima; Yutaka Kobayashi; Shigeo Horiike; Taira Maekawa; Masafumi Taniwaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

4.  Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.

Authors:  S Collins; H Coleman; M Groudine
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

5.  Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.

Authors:  H S Madapura; N Nagy; D Ujvari; T Kallas; M C L Kröhnke; S Amu; M Björkholm; L Stenke; P K Mandal; J S McMurray; M Keszei; L S Westerberg; H Cheng; F Xue; G Klein; E Klein; D Salamon
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

6.  Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs.

Authors:  T Nakamura; H Alder; Y Gu; R Prasad; O Canaani; N Kamada; R P Gale; B Lange; W M Crist; P C Nowell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.

Authors:  S J Collins
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

8.  BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Chunggang Gao; Wengang Chen; Qin Huang; Jiing-Kuan Yee; Ravi Bhatia; WenYong Chen
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

9.  Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

Authors:  Giulia Cheloni; Michele Tanturli; Ignazia Tusa; Ngoc Ho DeSouza; Yi Shan; Antonella Gozzini; Fréderic Mazurier; Elisabetta Rovida; Shaoguang Li; Persio Dello Sbarba
Journal:  Blood       Date:  2017-06-02       Impact factor: 22.113

10.  Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation.

Authors:  T Yasuda; T Ueno; K Fukumura; A Yamato; M Ando; H Yamaguchi; M Soda; M Kawazu; E Sai; Y Yamashita; M Murata; H Kiyoi; T Naoe; H Mano
Journal:  Leukemia       Date:  2013-09-26       Impact factor: 12.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.